These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38498565)

  • 1. Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes.
    King LM; Andrejko KL; Kabbani S; Tartof SY; Hicks LA; Cohen AL; Kobayashi M; Lewnard JA
    J Infect Dis; 2024 Mar; ():. PubMed ID: 38498565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric outpatient visits and antibiotic use attributable to higher valency pneumococcal conjugate vaccine serotypes.
    King LM; Andrejko KL; Kabbani S; Tartof SY; Hicks LA; Cohen AL; Kobayashi M; Lewnard JA
    medRxiv; 2023 Aug; ():. PubMed ID: 37662372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.
    Choi YH; Bertran M; Litt DJ; Ladhani SN; Miller E
    Lancet Public Health; 2024 Aug; ():. PubMed ID: 39153492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
    Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
    Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
    de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
    BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
    Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
    PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Clin Infect Dis; 2023 Feb; 76(3):e1062-e1070. PubMed ID: 35789262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom.
    Wilson M; Lucas A; Mendes D; Vyse A; Mikudina B; Czudek C; Ellsbury GF; Perdrizet J
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicountry Review of Streptococcus pneumoniae Serotype Distribution Among Adults With Community-Acquired Pneumonia.
    Grant LR; Begier E; Theilacker C; Barry R; Hall-Murray C; Yan Q; Pope V; Pride MW; Jodar L; Gessner BD
    J Infect Dis; 2024 Jan; 229(1):282-293. PubMed ID: 37665210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine.
    Méroc E; Fletcher MA; Hanquet G; Slack MPE; Baay M; Hayford K; Gessner BD; Grant LR
    Microorganisms; 2023 Jul; 11(7):. PubMed ID: 37512988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive Pneumococcal Disease Epidemiology and Serotype Replacement After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Ontario, Canada, 2007-2022.
    Grewal R; Hillier K; Deeks SL; Yeung AH; Wilson SE; Wijayasri S; Harris TM; Buchan SA
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae275. PubMed ID: 38868312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Jun; ():. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.